Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Integral Diagnostics Limited
  6. News
  7. Summary
    IDX   AU000000IDX2

INTEGRAL DIAGNOSTICS LIMITED

(IDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Notification regarding unquoted securities - IDX

11/08/2021 | 05:22pm EST

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

Announcement Summary

use only

Entity name

INTEGRAL DIAGNOSTICS LIMITED

Date of this announcement

Tuesday November 09, 2021

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

Total number of

ASX +security

+securities to be

code

Security description

issued/transferred

Issue date

IDXAA

PERFORMANCE RIGHTS

274,703

08/11/2021

For personal

Refer to next page for full details of the announcement

Notification of Issue, Conversion or Payment up of Unquoted

1 / 7

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

Part 1 - Entity and announcement details

For personal use only

1.1 Name of entity

INTEGRAL DIAGNOSTICS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2

Registered number type

Registration number

ACN

130832816

1.3

ASX issuer code

IDX

1.4 The announcement is

New announcement

1.5

Date of this announcement

9/11/2021

Notification of Issue, Conversion or Payment up of Unquoted

2 / 7

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

For personal use only

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")

Notification of Issue, Conversion or Payment up of Unquoted

3 / 7

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

only

ASX +security code and description

IDXAA : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

8/11/2021

use

Will these +securities rank equally in all respects from their issue date with the existing issued

+securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

personal

Provide details of the KMP or +associates being issued +securities.

Name of KMP

Name of registered holder

Number of +securities

157,371

Dr Ian Kadish

Dr Ian Kadish

39,219

Mr Paul McCrow

Mr Paul McCrow

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme

or a summary of the terms

Each Performance Rights is issued at no cost and entitles the participant to receive one fully paid ordinary share in the

Company, subject to satisfaction of conditions. For further details refer to the Remuneration Report contained in IDX's

2021 Annual Report accessible at: https://www.integraldiagnostics.com.au/reports/

Any other information the entity wishes to provide about the +securities the subject of this notification

For

Issue details

Number of +securities 274,703

Notification of Issue, Conversion or Payment up of Unquoted

4 / 7

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

For personal use only

Notification of Issue, Conversion or Payment up of Unquoted

5 / 7

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Integral Diagnostics Ltd. published this content on 08 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 November 2021 22:19:20 UTC.


ę Publicnow 2021
All news about INTEGRAL DIAGNOSTICS LIMITED
2021Integral Diagnostics Names New CFO
MT
2021Integral Diagnostics Announces Appointment of Craig White as Chief Financial Officer Ef..
CI
2021Integral Diagnostics Limited Announces Resignation of Rupert Harrington as Non-Executiv..
CI
2021Notification regarding unquoted securities - IDX
PU
2021Integral Diagnostics Limited completed the acquisition of The X-Ray Group.
CI
2021INTEGRAL DIAGNOSTICS : Acquires Radiology Business for $27 Million
MT
2021Integral Diagnostics Limited agreed to acquire The X-Ray Group for AUD 45.9 million.
CI
2021INTEGRAL DIAGNOSTICS' : After-Tax Net Profit Jumps 36% in FY21
MT
2021Integral Diagnostics Seeks Acquisitions
CI
2021Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended J..
CI
More news
Financials
Sales 2022 379 M 272 M 272 M
Net income 2022 34,3 M 24,6 M 24,6 M
Net Debt 2022 189 M 135 M 135 M
P/E ratio 2022 24,0x
Yield 2022 2,91%
Capitalization 825 M 589 M 591 M
EV / Sales 2022 2,67x
EV / Sales 2023 2,40x
Nbr of Employees 1 524
Free-Float 88,3%
Chart INTEGRAL DIAGNOSTICS LIMITED
Duration : Period :
Integral Diagnostics Limited Technical Analysis Chart | IDX | AU000000IDX2 | MarketScreener
Technical analysis trends INTEGRAL DIAGNOSTICS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 4,07 AUD
Average target price 5,17 AUD
Spread / Average Target 27,1%
EPS Revisions
Managers and Directors
Ian Kadish CEO, Executive Director & Managing Director
Anne Lockwood Chief Financial & Commercial Officer
Helen Kurincic Independent Non-Executive Chairman
John Atkin Independent Non-Executive Director
Raelene Murphy Independent Non-Executive Director
Sector and Competitors